CT47B1 Inhibitors
CT47B1 inhibitors are chemical compounds that specifically target the CT47B1 protein, a member of the Cancer/Testis (CT) family of proteins. This family is predominantly expressed in the testis and various cancerous tissues, but the exact function of CT47B1 is not thoroughly understood. It is believed that proteins like CT47B1 may play roles in cellular processes such as cell cycle regulation, division, or survival, especially in highly proliferative environments like reproductive tissues. Inhibitors of CT47B1 are designed to bind to this protein and alter its natural function, enabling researchers to study the impact of its inhibition on biological systems. These inhibitors are useful in research focused on understanding how CT47B1 participates in cellular mechanisms such as proliferation and differentiation.
CT47B1 inhibitors are diverse, with different scaffolds that allow for high specificity and affinity toward the CT47B1 protein. These inhibitors are often crafted to interact with the active or binding sites of CT47B1, blocking its ability to interact with other cellular components. By inhibiting CT47B1, researchers can disrupt the protein's involvement in signaling pathways and observe the resulting cellular changes. This enables scientists to probe the functional importance of CT47B1 in different contexts, such as in testis-related functions or in cellular processes where rapid growth or division is involved. CT47B1 inhibitors provide essential tools for unraveling the molecular underpinnings of this lesser-known protein, contributing to a deeper understanding of the Cancer/Testis family and its broader role in human biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
As an Aurora kinase A inhibitor, Alisertib disrupts the mitotic process which is crucial for the division and proliferation of cancer cells, leading to the inhibition of CT47B1 expression in testicular cancer by preventing cell cycle progression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
This proteasome inhibitor prevents the degradation of regulatory proteins involved in cell cycle control and apoptosis. By stabilizing these proteins, Bortezomib promotes apoptosis in cancer cells, thus indirectly inhibiting CT47B1 by reducing cancer cell survival. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
A histone deacetylase (HDAC) inhibitor that alters chromatin structure and gene expression. This can lead to the inhibition of CT47B1 by affecting the transcriptional environment in cancer cells where CT47B1 is typically overexpressed. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
A CDK4/6 inhibitor that arrests cancer cell proliferation by blocking the cell cycle progression at the G1 phase. Through this mechanism, this compound indirectly inhibits CT47B1 by limiting the proliferation of cancer cells that express this antigen. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
As a PARP inhibitor, Olaparib promotes DNA damage accumulation by preventing DNA repair, leading to cancer cell death. Consequently, this contributes to the inhibition of CT47B1 by reducing the viability of cells expressing it. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
By inhibiting multiple tyrosine kinases, including VEGFR, PDGFR, and c-KIT, Pazopanib disrupts angiogenesis and cell proliferation. This multi-targeted approach contributes to the inhibition of CT47B1 by limiting the growth of tumors that express this antigen. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $214.00 $622.00 | 1 | |
This HDAC inhibitor changes the expression of genes involved in cell cycle arrest and apoptosis. Romidepsin can lead to the inhibition of CT47B1 in cancer cells by modifying the transcriptional landscape where CT47B1 is usually upregulated. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $178.00 $648.00 $1657.00 | 3 | |
A multikinase inhibitor that affects VEGFR, FGFR, PDGFR, and others, Lenvatinib inhibits angiogenesis and lymphogenesis in tumors, thereby indirectly inhibiting CT47B1 by impeding the growth of CT47B1-positive cancer cells. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
By inhibiting MEK, Cobimetinib affects the MAPK/ERK pathway which is fundamental for cell proliferation and survival. This can lead to inhibition of CT47B1 by altering the environment in which CT47B1-expressing cells proliferate. | ||||||